Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects.
about
Defensive eye-blink startle responses in a human experimental model of anxiety.Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humansCarbon dioxide inhalation induces dose-dependent and age-related negative affectivityTransient acidosis while retrieving a fear-related memory enhances its lability.Inhalation of 7.5% carbon dioxide increases threat processing in humans.Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.Transient state-dependent fluctuations in anxiety measured using STAI, POMS, PANAS or VAS: a comparative review.Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets.Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function.The effects of opioid receptor blockade on experimental panic provocation with CO2.The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures.A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO2 challenge.The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.Oxytocin interference in the effects induced by inhalation of 7.5% CO(2) in healthy volunteers.The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers.Effects of 7.5% CO2 challenge in generalized anxiety disorder.Effects of acute exercise on CO(2) -induced fear.
P2860
Q30381984-E627CE08-20C4-4CA2-95B5-717622A33DA7Q30431029-D93D7558-68DF-4D7F-98C0-AEB4E4DAA8A4Q33301340-C0DD006F-7ED4-4B56-9280-B8800825B901Q33835038-DB9A621C-0F61-4A48-B5AD-82A4F523B8DCQ35112168-C7F13947-62B1-42A9-9EF9-F1209A6AF14EQ37686937-530EA61D-9CA1-4C29-8792-DB36A9C48E85Q37914191-DB75751D-24C8-4D25-8D4C-F4E9BF17110AQ39183229-18E8ECB4-9285-4A59-9382-F366A5E4BD2AQ44130094-B8CE84C7-B063-4D5F-B304-1077FE5ECC5FQ44339535-DEB5683B-4762-4C34-8676-53A1192CAC9AQ46334050-2325E168-745C-4411-8021-1991D41B5589Q46988489-6CC11A76-C288-47D4-8994-631DE801FB2DQ47971036-09D86FA8-486E-4FB9-89BE-9D0F03CABE83Q50555256-35A55D0E-CAFC-475A-A8ED-E0FC4989CE39Q50574443-247CDC5D-94AF-4F38-B838-455D8C2E0E6CQ50673543-2E609783-FC5F-4D4D-B3E5-A652A1CBCAC3Q50702395-E660F1D1-C015-40BB-A21B-7E2BAFC334DCQ50787856-8CFDCD00-5BA5-4D61-BF6B-8180F4B0CABE
P2860
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Characterization of a 7% carbo ...... symptoms in healthy subjects.
@en
Characterization of a 7% carbon dioxide
@nl
type
label
Characterization of a 7% carbo ...... symptoms in healthy subjects.
@en
Characterization of a 7% carbon dioxide
@nl
prefLabel
Characterization of a 7% carbo ...... symptoms in healthy subjects.
@en
Characterization of a 7% carbon dioxide
@nl
P2093
P2860
P356
P1476
Characterization of a 7% carbo ...... symptoms in healthy subjects.
@en
P2093
Emilio Merlo-Pich
Gianluca Nucci
Giulia I Perini
Lisa Squassante
Massimo Bani
Stefano Milleri
Stefano Zanone Poma
P2860
P304
P356
10.1177/0269881105056533
P407
P577
2005-09-01T00:00:00Z